New urine test detects 95% of bladder cancer cases in study: What patients should know

A groundbreaking urine test has shown remarkable accuracy in detecting bladder cancer, potentially revolutionizing early diagnosis and treatment. The study, published in Nature Medicine, evaluated the test's ability to identify 95% of bladder cancer cases, even in their early stages, by analyzing cell-free RNA molecules present in urine samples.

Unlike traditional blood-based liquid biopsy tests that primarily detect DNA released by tumors, this innovative technique focuses on RNA, which carries information about cellular activity. Dr. Sheeba Santhmayer, a Consultant Radiation Oncologist at TGH ONCO LIFE Cancer Centre, explains that the urine test could offer a less invasive alternative to traditional diagnostic procedures like cystoscopy, which uses a camera to examine the bladder for suspicious growths.

While the test's 95% sensitivity is a promising indicator of its effectiveness, researchers stress that further clinical validation is necessary to confirm its accuracy and reliability across diverse patient populations and to determine its potential for detecting other urological cancers, such as kidney and prostate cancers. The technology remains in the early stages and is not yet available for clinical use.